Sargent Investment Group LLC Cuts Holdings in Johnson & Johnson (NYSE:JNJ)

Sargent Investment Group LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,441 shares of the company’s stock after selling 338 shares during the quarter. Sargent Investment Group LLC’s holdings in Johnson & Johnson were worth $3,475,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Omnia Family Wealth LLC lifted its stake in Johnson & Johnson by 22.3% in the third quarter. Omnia Family Wealth LLC now owns 3,033 shares of the company’s stock worth $492,000 after purchasing an additional 553 shares during the last quarter. Intelligence Driven Advisers LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $243,000. Tokio Marine Asset Management Co. Ltd. boosted its holdings in Johnson & Johnson by 5.4% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 66,313 shares of the company’s stock valued at $10,747,000 after acquiring an additional 3,392 shares during the period. Metis Global Partners LLC grew its position in Johnson & Johnson by 3.2% in the 3rd quarter. Metis Global Partners LLC now owns 138,758 shares of the company’s stock valued at $22,487,000 after acquiring an additional 4,283 shares during the last quarter. Finally, Curi RMB Capital LLC increased its stake in Johnson & Johnson by 2.2% in the third quarter. Curi RMB Capital LLC now owns 104,083 shares of the company’s stock worth $16,868,000 after purchasing an additional 2,239 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.9 %

Shares of Johnson & Johnson stock opened at $151.86 on Friday. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The firm’s 50 day moving average price is $161.82 and its 200-day moving average price is $155.99. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company has a market cap of $365.62 billion, a P/E ratio of 21.98, a PEG ratio of 2.72 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the prior year, the firm posted $2.66 earnings per share. The business’s quarterly revenue was up 5.2% on a year-over-year basis. On average, sell-side analysts predict that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.27%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This represents a 22.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Citigroup raised their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Wells Fargo & Company increased their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Morgan Stanley upped their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $175.00.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.